Cytokinetics Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. The company’s lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure.

CK-2017357, a skeletal muscle activator, is being developed by Cytokinetics independently as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis.

Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as systemic hypertension or bronchoconstriction. All of Cytokinetics’ drug candidates and potential drug candidates have been discovered via the company’s research activities and are directed towards the cytoskeleton.

As of last report, Cytokinetics had $82.9 million in total assets, with $30.4 million in cash and equivalents, and $6.8 million in total liabilities. Insiders hold 14.4% of the shares outstanding while institutions hold 54.20%. Five analysts currently offer coverage of the company with price targets ranging from $6.00 to $11.00. Currently trading around $1.90 a share, Cytokinetics has an approximate $124 million dollar market cap.